<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 CFR 211.103</td>
<td>Yield calculation</td>
<td>17</td>
</tr>
<tr>
<td>21 CFR 211.132</td>
<td>Tamper-evident packaging</td>
<td>17</td>
</tr>
<tr>
<td>21 CFR 211.137</td>
<td>Expiration dating</td>
<td>18</td>
</tr>
<tr>
<td>21 CFR 211.166</td>
<td>Stability testing</td>
<td>19</td>
</tr>
<tr>
<td>21 CFR 211.165</td>
<td>Testing/release for distribution</td>
<td>22</td>
</tr>
<tr>
<td>21 CFR 211.167</td>
<td>Special testing requirements</td>
<td>25</td>
</tr>
<tr>
<td>21 CFR 211.170</td>
<td>Reserve samples</td>
<td>26</td>
</tr>
<tr>
<td>21 CFR 211</td>
<td>as Primary cGMP</td>
<td>30</td>
</tr>
<tr>
<td>21 CFR 820.20</td>
<td>Management responsibility</td>
<td>30</td>
</tr>
<tr>
<td>21 CFR 820.30</td>
<td>Design controls</td>
<td>34</td>
</tr>
<tr>
<td>21 CFR 820.50</td>
<td>Purchasing controls</td>
<td>41</td>
</tr>
<tr>
<td>21 CFR 820.100</td>
<td>Corrective and preventive actions</td>
<td>42</td>
</tr>
<tr>
<td>21 CFR 820.170</td>
<td>Installation</td>
<td>44</td>
</tr>
<tr>
<td>21 CFR 820.200</td>
<td>Servicing</td>
<td>45</td>
</tr>
<tr>
<td>Risk Management in cGMP</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>About the Author</td>
<td>49</td>
<td></td>
</tr>
</tbody>
</table>

### 3 RISK MANAGEMENT FOR COMBINATION PRODUCTS

*Edwin Bills*

- Introduction                                           | 51   |
- Complications for Combination Products                  | 52   |
- Risk Definition                                         | 54   |
- Medical Devices                                         | 54   |
- Pharmaceuticals and Biologics                            | 55   |
- Health Product Risk Management                           | 58   |
- The Risk Management Process                             | 58   |
- Hazard Identification                                    | 62   |
- Hazardous Situation                                     | 65   |
- Risk Estimation                                         | 65   |
- Risk Control                                            | 71   |
- Overall Residual Risk Evaluation                         | 76   |
- Risk Management Report                                   | 78   |
- Production and Post-Production                           | 79   |
- Summary                                                 | 82   |
- References                                              | 83   |
- About the Author                                         | 85   |
6 CROSS LABELED COMBINATION PRODUCTS 125
Suzanne O’Shea
Introduction 125
What are Cross Labeled Products? 126
Differences from General Use Devices 128
Marketing Applications 129
Mutually Conforming Labelling 130
Intent to Cross Label 132
Cross Labeling Challenges 133
Conclusion 134
References 135
About the Author 136

7 REGULATORY STRATEGIES FOR COMBINATION PRODUCTS 137
William D’Agostino
US FDA Regulatory Process 139
PMOA and Project Risks 140
Strategies for Development and Launch 141
Fast-Track Drug-Device Approval 142
PMOA Roadmap 143
European Union 149
   EU products with device PMOA 149
   EU products with drug PMOA 150
Combination Product Intellectual Property 152
Summary 152
References 152
About the Author 154

8 DEVELOPMENT OF A DRUG/AUTOINJECTOR COMBINATION PRODUCT: A CASE STUDY 155
Mark A. Chipperfield, Ruby Gulati and Jennifer Mercer
Introduction 155
cGMP for Combination Products 156
Development of a Combination Product 157
Case Study Background 157
   Development of the autoinjector 159
   Quality systems 160
   Risk management 161